In this interview, Stephane Moreau (Shimadzu Europa) introduces the new Q-TOF LCMS-9030 instrument among other technologies available for automation and microsamping.
For therapeutic drug development and monitoring, microsampling technology provides a breakthrough alternative
One useful way to think about volumetric absorptive microsampling (VAMS) technology is as the next generation of traditional dried blood spot (DBS) cards. It’s a simpler method that makes it easier to collect blood and prepare it for analysis. With minimal training, the microsampling process can be self-administered anywhere, through a procedure that is less difficult and generally less expensive than working with conventional venous blood. Other benefits include a more pleasant patient experience, which leads to greater adherence and compliance, and freer access to remote areas of the world.
The journal, the Society for Laboratory Automation and Screening Technology, presents a special issue highlighting the development of research assays.
In this Column, Stuart A. Kushon (Neoteryx; CA, USA) discusses what he feels is the key to successful implementation of microsampling.
Available to view on demand: In this webinar, Adam Hill discusses the changes and challenges in early drug discovery, including new and more efficient discovery strategies.
In this article, Eric Tewalt and James Gorman discuss updates and considerations for the utilization of hybridization ELISA methods, including associated benefits and challenges, for the bioanalysis of oligonucleotides.
Jeff Duggan, Director, Bioanalytical Mass Spectrometry, Boehringer-Ingelheim Pharmaceuticals (CT, USA) started his career in pharmaceutical…
Bridging immunogenicity assays for IgG4 therapeutics: mitigating interference from Fc–Fc interactions
In this research article, the authors investigate the advantages and disadvantages of an immunogenicity assay for a human IgG4 mAb therapeutic being transferred to an automated system.
PPD has announced their vaccine research laboratory expansion, enhancing its capabilities in supporting vaccine development programs.
Martijn Hilhorst studied analytical chemistry at the University of Amsterdam followed by a PhD period…